Arcutis Stock Up 65% as Director Sells 10,000 Shares Under 10b5-1 Plan. Here's What Investors Should Know

Transaction worth based connected SEC Form 4 reported terms ($23.88); post-transaction worth based connected trade-date marketplace adjacent price.

• How does the size of this merchantability comparison to erstwhile transactions by Howard G. Welgus?
  This 10,000-share merchantability matches the emblematic monthly trading cadence observed since 2023, accordant with anterior idiosyncratic merchantability sizes which person ranged from 9,208 to 10,139 shares.

• What percent of Howard G. Welgus's holdings does this transaction represent, and what does that bespeak astir remaining capacity?
  The merchantability comprised 20% of his nonstop communal banal holdings earlier the transaction, leaving him with 39,744 shares, oregon lone astir 14.3% of his starting holdings from 2 years prior, indicating a much-diminished capableness for aboriginal income astatine this scale.

* 1-year show calculated utilizing April 1, 2026 arsenic the notation date.

• Arcutis Biotherapeutics develops and commercializes topical therapies for dermatological diseases, including plaque psoriasis, atopic dermatitis, seborrheic dermatitis, scalp psoriasis, manus eczema, vitiligo, and alopecia areata.

• The steadfast generates gross done the development, approval, and commercialization of proprietary medicine treatments, chiefly leveraging its pb merchandise candidates ARQ-151 (roflumilast cream) and ARQ-154 (roflumilast foam).

• It targets dermatologists and healthcare providers treating patients with chronic inflammatory tegument conditions successful the United States and prime planetary markets.

Arcutis Biotherapeutics operates arsenic a clinical-stage biopharmaceutical institution with a absorption connected innovative topical therapies for dermatological conditions. The company's strategy centers connected leveraging differentiated formulations of established molecules to code unmet needs successful chronic tegument diseases. Its competitory borderline lies successful its robust late-stage pipeline and expertise successful topical cause improvement for large, underserved diligent populations.